Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca^(2+)/CaMKII pathway  

作　　者：Congyu Ma Ning Sheng Jun Wu Lulu Wang Jiandong Jiang Haibo Yu Jinlan Zhang 

机构地区：[1]State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100050,China [2]Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100050,China

出　　处：《Journal of Pharmaceutical Analysis》2024年第3期435-438,共4页药物分析学报（英文版）

基　　金：the National Natural Science Foundation of China(Grant No.:82204341);Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(Grant No.:2022-I2M-2-002);the National Key Research and Development Program of China(Grant No.:2019YFC1708901).

摘　　要：Abnormal synaptic plasticity causes cognitive deficits.Hippocampal long-term potentiation(LTP)is a critical synaptic plasticity process[1].Rescuing impaired LTP is challenging;hence,novel agents are required for LTP facilitation.Chinese medicine Dengzhan Shengmai(DzSM)has shown notable clinical efficacy against cognitive deficits[2].However,it remains unclear how DzSM modulates cognition.Our previous study[3]revealed the influence of DZSM on glutamatergic and GABAergic synapses following chronic cerebral hypoperfusion(CCH),which motivated us to assess how DzSM affects synaptic functions.

关 键 词：IMPAIRED IMPAIRMENT hence 

分 类 号：R285.5[医药卫生—中药学]